(Information sent by the signatory company)
EJBY, Denmark, Nov. 30, 2023 /PRNewswire/ — Today Scantox, together with its majority owner Impilo, has agreed to acquire the neuropharmacology division of QPS Austria GmbH (“QPS Neuro” or “the Company”), ultimately owned instance of QPS Holdings LLC. QPS Neuro is a leading drug discovery contract research organization (CRO) specializing in neurodegenerative, rare diseases and mental disorders. The Company is renowned for its high-quality services that are deeply scientifically rooted and has an undisputed track record of serving a broad and loyal customer base globally. This transformative acquisition will expand Scantox’s value chain coverage and significantly reposition its existing drug discovery platform with unique and market-leading central nervous system (CNS) research capabilities.
Founded in 1999, QPS Neuro has a long history of developing expertise in lead optimization services and effectiveness studies. The company has a 2,700 square meter state-of-the-art facility in Grambach, Austria, and employs more than 80 people. With in situ availability of validated transgenic and non-transgenic in vitro and in vivo models, QPS Neuro addresses multiple targets within the growing area of ??the CNS and represents a unique partner for biotechnology and pharmaceutical companies in their drug development process.
“The acquisition of QPS Neuro is significantly changing our lead optimization platform and expands the depth and breadth of our discovery services in the CNS and rare disease area. We see a strong fit with the Scantox organization and are deeply impressed with the dedicated management staff and their R&D efforts were focused on providing a higher level of service and scientific excellence to their customers,” said Jeanet Løgsted, CEO of Scantox.
Manuela Prokesch, Director of QPS Neuro, continues: “This is a unique opportunity for us to join a preclinical market leader, known for its high quality and customer-centric approach. We look forward to leveraging synergies across the Scantox organization while We continue to offer the best personalized solutions to our clients.
QPS Neuro will continue operations as part of the Scantox group. The combined company will have more than 300 employees across six sites offering discovery models including neuropharmacology research services, regulatory toxicology and CMC/analytical services.
Nicholas Hooge, Partner at Impilo, concluded: “This is a transformative acquisition for Scantox that significantly expands its service offering and client reach. We are delighted to welcome the QPS Neuro team to the Scantox group and see significant growth opportunities. for the combined business going forward. “As demonstrated by this acquisition, Impilo continues to have a strong conviction in the broader preclinical market and looks forward to continuing to work with the enlarged group to further expand its service offering and strengthen its position globally.” .
Loan linked to sustainability
As part of the transaction, Scantox has successfully signed a sustainability-linked loan in collaboration with Nordea and Nykredit. The loan reflects the company’s proactive approach to integrating sustainable practices into its business strategy.
Advisors
Lincoln International acts as corporate financial advisor to Scantox, EY acts as financial and tax advisor, L.E.K. Consulting as commercial advisor and Accura together with DORDA act as legal advisors. Perella Weinberg Partners acts as financial advisor to QPS Holdings, KPMG acts as tax advisor and Ropes
For more information, contact:
Dr. Manuela Prokesch, Director of QPS Neuro, Manuela.Prokesch@qps.com
Nicholas Hooge, Partner at Impilo, Nicholas.Hooge@Impilo.se
About Scantox
Scantox is the leading Nordic GLP-accredited preclinical CRO, focused on pharmacology and regulatory toxicology, headquartered in Denmark with subsidiaries in Sweden and Denmark. With decades of experience, Scantox is a trusted partner for product development services within the pharmaceutical, biotechnology and medical device industries, with world-renowned expertise within the Göttingen minipigs. Scantox’s services allow clients to advance the development of their medicines or devices based on solid data and with the highest technical and scientific standards. Founded in 1977, Scantox is today owned by Impilo, the leading Nordic healthcare investment company.
About QPS Neuro
QPS Neuro, the neuropharmacology division of QPS Austria GmbH, is highly experienced and specialized in preclinical CNS services. QPS Neuro has built its reputation since 1999 as a high quality CRO and leading specialist in Alzheimer’s, Parkinson’s, ALS, Dementia, Niemann-Pick, Gaucher, Autism, Schizophrenia, Frontotemporal Lobe Degeneration and other neurodegenerative and rare diseases. The company’s reputation within CNS is further enhanced by its strong capabilities in preclinical efficacy studies including in vitro molecular and cellular analyzes and proprietary in vivo transgenic mouse and rat models with associated assays offered to a broad portfolio of clients. .
About Impilo
Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies active in pharmaceuticals, medical technology, healthcare services and other health-related areas. Impilo strives to increase the value of your investments through long-term active ownership. Impilo has a well-diversified investment portfolio and has raised close to €1 billion in capital from leading Nordic and international investors since its inception in 2017.
Logo – https://mma.prnewswire.com/media/2288707…
View original content: https://www.prnewswire.com/news-releases/scantox-adquiere-la-division-de-neurofarmacologia-de-qps-austria-302001825.html
